-
-
-
-
-
-
-
Clearmind completes Part A of Phase I/II trial for alcohol disorder drug
-
-
-
-
-
-
-
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
-
-
-
-
-
-
-
Clearmind Medicine receives new U.S. patent for binge behavior treatments
-
-
-
-
-
-
-
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
-
-
-
-
-
-
-
Clearmind Medicine announces 1-for-10 reverse stock split effective May 21
-
-
-
-
-
-
-
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
-
-
-
-
-
-
-
Clearmind Medicine meets safety endpoint in alcohol disorder trial
-
1,177,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

